If Medicare Part D has denied, delayed, or restricted coverage for an FDA-approved JAK inhibitor (Olumiant, Litfulo, Leqselvi) prescribed for alopecia areata, we want to hear from you.
Not sure if your plan is part of Medicare Part D? If you've received a denial letter for coverage of your FDA-approved JAK inhibitor, we'd like to see it.
Your experience matters. This information will be solely used to advocate for fair Medicare Part D coverage of FDA-approved alopecia areata treatments. All information is kept confidential.
Instructions: This form takes about 10-15 minutes. Before you start, collect your insurance card and your written denial letter. No letter? You can still submit information about your denial.
You will be asked to upload a photo (JPG or PNG) or a scanned document (PDF) of your letter, if you have one. Before uploading, please make a copy of your original letter and keep the original letter for your records. To protect your privacy, on the copy, please black out the following using a marker or other tool:
- Medicare ID number
- Social Security number
- Date of birth
- Full mailing address
- Phone number
- Email address